natgillin/translations-raw huggingface dataset:
The method of claim 1 wherein the maximum plant power, PMax(t), and/or the minimum plant power, PMin(t) are calculated through specific values of irradiance, G(t), and measured cell temperatures (Tc), wherein the intermittent power generation plant is a photovoltaic plant. 
Metoda za kontrolu brzine napajanja koja minimizira zahtjeve za skladištenjem energije u povremenim postrojenjima za proizvodnju električne energije u skladu s patentnim zahtjevom 1, naznačena time što se izračunavaju najveća snaga postrojenja, Py,x(t) i / ili minimalna snaga postrojenja, Pyn(t) pomoću specifičnih vrijednosti zračenja, G(t), i izmjerenih temperatura stanica (T.), pri čemu je povremeno postrojenje za proizvodnju energije fotonaponsko.
Upwardly oriented storage according to claim 28, wherein the plunger drive is adapted to place the plunger in a third position in which it by its form and positioning substantially covers the input opening, and whereby a returnable item which has been received in the input area is blocked from falling through the input opening by remaining on the plunger when the plunger is placed in the third position. 
Prema gore orijentirano skladište prema patentnom zahtjevu 19, naznačeno time, što je pogon klipa prilagođen da postavi klip u treći položaj u kojem on svojim oblikom i pozicioniranjem značajno pokriva ulazni otvor, i pri čemu je povratni artikal koji je primljen u ulaznom području blokiran od pada kroz ulazni otvor tako što ostaje na klipu kada se klip stavi u treći položaj.
An anti-tumor agent according to claim 40, wherein the tumor is a pancreatic cancer, a gastric cancer, a colon cancer, a breast cancer, a prostrate cancer, a lung cancer, a renal cancer, a brain tumor, a blood cancer or an ovarian cancer. 
Spoj prema zahtjevu 1 za liječenje raka prema zahtjevu 11, naznačen time, da rak je rak gušterače, rak želuca, rak debelog crijeva, rak dojke, rak prostate, rak pluća, rak bubrega, tumor mozga, rak krvi ili karcinom jajnika.
The composition of claim 1, wherein the divalent or trivalent cation is selected from magnesium, calcium, zinc, copper, aluminum, and iron. 
Aerosol za uporabu sukladno patentnom zahtjevu 1 ili patentnog zahtjeva 2, pri čemu se dvovalentni ili trovalentni kation odabire iz magnezija, kalcija, cinka, bakra, aluminija i željeza.
The pharmaceutical composition according to any one of claims 6 to 12, which is formulated for oral, parenteral, subcutaneous, intravenous, intramuscular, nasal, topical or rectal administration. The pharmaceutical composition according to any one of claims 6 to 13, comprising one or more pharmaceutically acceptable excipients. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 6 do 9, naznačen time što je formuliran za oralnu, parenteralnu, supkutanu, intravensku, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu, i/ili što sadrži jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
applying a pressure on the first and the second sawn timber board by a third and a fourth element, in a direction perpendicular to a top surface of the second sawn timber board, until the distance strips are bonded to the first and the second sawn timber board and thereby obtaining a solid batch; and 
primjenu pritiska (P3) na prvu i drugu rezanu drvenu ploču pomoću trećeg i četvrtog elementa (72,73), u smjeru okomito na gornju površinu druge rezane drvene ploče, sve dok odstojne trake nisu vezane na prvu i drugu rezanu drvenu ploču čime dobiva kruti stog; i *
It is also preferred that the barnacle material comprised in the product only comprises nauplius stage I, or only comprises eggs, or only comprises a combination of nauplius stage I with eggs and/or nauplius stage II of a barnacle. 
Hrana za životinje prema bilo kojem od prethodnih zahtjeva, pri čemu materijal raka vitičara sadržan u hrani za životinje sadrži samo nauplije stadija I, ili sadrži samo jaja, ili sadrži samo kombinaciju nauplija stadija I s jajima i/ili nauplijima stadija II raka vitičara.
The method of claim 2 wherein the pore size of the virus filter is between about 15 and about 30 nm diameter. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time, da je veličina pora virusnog filtera u promjeru između 15 130 nm.
a physiologically acceptable salt thereof, or a physiologically acceptable solvate thereof. 
njihova fiziološki prihvatljiva sol, ili njihov fiziološki prihvatljiv solvat.
Both classes of compounds have in common, at position 9, a group that can be selected from C1-C4 dialkylamine, 4-alkyl-1-piperazinyl, 4-hydroxyalkyl-1-piperazinyl, 4-alkyl-1-piperidinyl, and 4-alkyl-1-homopiperazinyl. 
Obje skupine spojeva imaju zajedničko, na položaju 9, skupinu koja možc biti izabrana iz C,-C, dialkilamina, 4-alk1l-1-piperazinila, 4-hidroksialkil-1-piperazinil, 4-alkil-1-piperidinil, te 4-alkil-1-homopiperazinil.
A nucleic acid molecule encoding the chimeric peptide of any one of claims 1 to 9, wherein the nucleic acid molecule further comprises an expression control element in operable linkage that confers expression of the nucleic acid molecule encoding the peptide in vitro, in a cell, or in vivo. 
Molekula nukleinske kiseline koja kodira himerni peptid sukladno bilo kojem od zahtjeva 1 do 9, pri čemu molekula nukleinske kiseline nadalje sadrži element za kontrolu ekspresije u operativnom povezivanju koji daje
The pharmaceutical composition according to claim 19, wherein said inflammatory bowel disease is selected from the group consisting of Crohn's disease and ulcerative colitis. 
Farmaceutski sastav u skladu s patentnim zahtjevom 12, pri čemu je navedena upalna bolest crijeva odabrana iz grupe koja se sastoji od Chronove bolesti i ulceroznog kolitisa.
The multiparticulate composition of claim 2, wherein the continuous proteinaceous subcoating is adapted to prevent the peppermint oil from mixing with the enteric coating. 
neprekidni proteinski podsloj koji prekriva jezgru je prilagođen da spriječi miješanje jednog ili više djelatnih sastojaka na bazi terpena s enteričkim premazom.
Plasma is separated and frozen within 30 min after collection and later analyzed. 
Plazma je odvojena i zamrznuta tijekom 30 min nakon uzimanja, a analizirana je kasnije.
Pharmaceutical composition or dosage form for use of claim 38, wherein said crystalline trans-(±)-A9-THC comprises at least 95%, preferably at least 98%, more preferably at least 99%, even more preferably at least 99,5% and most preferably at least 99,9% by weight of the total amount of cannabinoids in said composition or dosage form. 
Farmaceutski sastav ili oblik doziranja za upotrebu prema zahtjevu 38, naznačen time da kristalni trans-(±)-A9-THC sadrži barem 95%, poželjno barem 98%, poželjnije barem 99%, još poželjnije barem 99.5% i najpoželjnije barem 99.9% težine ukupne količine kanabinoida u navedenom sastavu ili obliku doziranja.
The composition according to claim 1, comprising 10-50% w/w of the lipid carrier. 
Kompozicija prema bilo kojem od zahtjeva 1-11, pri čemu je pogonsko sredstvo dimetil eter.
The sole for shoes according to claim 15, characterized in that said wider portion (226b) tapers downwardly. 
Potplat za cipele u skladu s patentnim zahtjevom 15, naznačen time, da se navedeni širi dio (226b) sužava prema dolje.
The combination according to any one of claims 1 to 4, which is a compound selected from the group consisting of: 
Spoj prema patentnom zahtjevu 1, naznačen time što je to spoj izabran iz grupe koju čine:
The compound or salt for use as in claim 3, wherein the dose is administered in separate administrations of 2 equal doses. 
Spoj ili sol za uporabu prema zahtjevu 15, gdje se doza daje u odvojenim primjenama od 2 jednake doze.
providing at least a core layer (1) for said article, which core layer (1) comprises a flexible, open-cell foam having voids forming at least 90% of the volume of the open-cell foam; 
Priprema najmanje jednog sloja jezgre (1) za proizvod, pri čemu sloj jezgre (1) obuhvaća fleksibilnu otvorenostaničnu pjenu s otvorenim porama,
an antisense oligomer which consists of a nucleotide sequence having at least 90% identity with a nucleotide sequence of SEQ ID NO: 7, 8 or 9 and has an activity to cause skipping of the 51st exon in the human dystrophin gene; and 
antisensni oligomer koji ima nukleotidnu sekvencu koja ima najmanje 90% istovjetnosti s nukleotidnom sekvencom SEQ ID NO: 1 ili 2 i ima aktivnost izazvati preskakanje 51-vog egzona u humanom distrofinskom genu.
A compound or pharmaceutically acceptable salt, enantiomer or diastereomer according to any one of claims 1 to 11 for use in the treatment or prophylaxis of hepatitis B virus infection. 
Spoj ili farmaceutski prihvatljiva sol, enantiomer ili dijastereomer prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da se upotrebljava u liječenju ili profilaksi infekcije virusom hepatitisa B.
The Fc-containing molecule of embodiment 1, wherein the Fc-containing molecule is an antibody or Fc fusion protein. 
Molekula koja sadrži Fc iz zahtjeva 1, gdje je molekula koji sadrži Fc antitijelo ili Fc fuzijski protein.
a smaller molar amount of the fusion protein is administered to a subject in comparison to the corresponding GH that lacks the XTEN administered to a subject under an otherwise equivalent dose regimen, and the fusion protein achieves a comparable therapeutic effect as the corresponding GH that lacks the XTEN; or 
(iii) se na pojedincu primjenjuje jedna manja molarna količina fuzijskog proteina u usporedbi s odgovarajućim GH kojemu nedostaje XTEN i koji se primjenjuje na pojedincu pod nekim drugim ekvivalentnim doznim režimom, te da fuzijski protein postiže usporedivi terapeutski učinak kao odgovarajući GH kojemu nedostaje XTEN,; ili
Construction of the pcSDhuCTLA4-Ig Expression Vector: 
Datum podnošenja europske prijave patenta:
The residue was dissolved in 250 mL of chloroform and washed with 50 mL of water. 
Ostatak se otopi u 250 mL kloroforma i ispere s 50 mL vode.
removing the G groups to form a compound of formula (VIIa) or (VIIb): 
(d) uklanjanje G grupa da bi se formirao spoj formule (VIIa) ili (VIIb):
The process of clause 54, wherein the solutions in steps (a) and (c) each comprise the same ether solvent. 
Postupak prema patentnom zahtjevu 35, pri čemu svaka od otopina u koracima (a) i (c) sadrži isto etersko otapalo.
In the Tables, the label RUS0350 refers to Isomer B. 
U Tabelama, oznaka RUS0350 se odnosi na Izomer B.
The method of clause 131 wherein the antibody comprises an anti-IL-6 antibody or fragment according to one of clauses 1 or 82-89. 
Slijed nukleinskih kiselina koji kodira anti-IL-6 protutijelo sukladno bilo kojem od patentnih zahtjeva 1-3.
and R2 represent independently hydrogen, or C1-6 alkyl with straight or branched chain optionally substituted with C1-6 alkoxycarbonyl, or phenyl or R1 and R2 form with the adjacent nitrogen atom an optionally by C1-6 alkyl or hydroxy substituted pyrrolidine, piperazine, piperidine or morpholine ring; 
R; i R2 predstavljaju neovisno vodik, ili Cis alkil s ravnim ili razgranatim lancem opcijski supstituiran s Cig alkoksikarbonilom, ili fenilom, ili R; 1 R> tvore sljedeće prstene, opcijski supstituirane sa C,.g alkilom ili hidroksi: pirolidin, piperidin ili morfolin prsten. alil; fenil opcijski supstituiran s jednim ili više od sljedećih: C1.4 alkoksi, cijano ili
A kit for treating a tumor comprising (a) a pharmaceutical composition comprising, as an active ingredient, a compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof and (b) a pharmaceutical composition comprising, as an active ingredient, at least one other antitumor agent, in combination. 
Komplet za liječenje tumora, naznačen time što sadrži (a) farmaceutski pripravak koji kao aktivni sastojak sadrži spoj formule [I] u skladu s patentnim zahtjevom 24, ili njegovu farmaceutski prihvatljivu sol, i (b) farmaceutski pripravak koji kao aktivni sastojak sadrži najmanje još jedno antitumorsko sredstvo, u kombinaciji.
The composition according to any one of claims 1 to 5 additionally comprising at least one auxiliary selected from the group consisting of extenders, solvents, spontaneity promoters, carriers, emulsifiers, dispersants, frost protectants, thickeners and adjuvants. 
Pripravak prema bilo kojem od zahtjeva 1 do 5 naznačen time što dodatno sadrži barem jedan pomoćni sastojak odabran iz skupine koja se sastoji od punila, otapala, promotora spontanosti, nosača, emulgatora, disperzanta, zaštitnih sredstava za mraz, zgušnjivača i pomoćnih sredstava.
Figures 7 and 8 provide similar details concerning the connection of the outputs of the receiver to the joysticks, or equivalent switches, that control the bow and stem thrusters, respectively. 
Slike 7 i 8 prikazuju slične pojedinosti koje se tiču spajanja izlaza prijemnika na palice ili ekvivalentne sklopke, koje upravljaju pramčanim, odnosno krmenim vijcima.
1 with extrusion ridge 17, whereat within the storage space a lighter 19 is placed. 
1 sa udubljenim rubom 17, gdje je u spremišnom prostoru stavljen upaljač 19.
The invention therefore also relates to a method for the treatment of an IBD, in particular of ulcerative colitis or Crohn's disease, comprising administering to a patient in need thereof a formulation according to the invention. 
- < za uporabu u metodi za liječenje bolesti odabrane iz grupe koja se sastoji od kronične bubrežne bolesti (CKD), upalnih bolesti crijeva (IBD-ova), posebno ulcerativnog kolitisa ili Chronove bolesti i hepatalne encefalopatije;
The method as claimed in claim 1, further comprising in the preview region showing at least one of the properties from the group—dispensing volume of the chosen beverage, composition of the chosen beverage, flavor additives of the chosen beverage—graphically at least in part, wherein the dispensing volume is shown by a size representation of a dispensing receptacle, or the composition is shown by layers of different color or a flavor additive is shown by a pictogram assigned to said flavor. The method as claimed in claim 1, further comprising the selection mode is realized as a credit mode in which a credit of the user is displayed by a price being assigned to each beverage variant and only such beverage variants having a price which is less than or equal to the credit is selectable. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što u području pregleda prikazuje se, u najmanju ruku dijelom u grafičkom obliku, najmanje jedna od karakteristika iz skupine: izlazni volumen odabranog napitka, sastav odabranog napitka, dodatne arome odabranog napitka, gdje se osobito izlazni volumen prikazuje opisom veličine posude za prihvat izlaza, osobito šalice, šalice za espresso kavu ili čaše, i/ili se sastav prikazuje slojevima različitih boja, i/ili se dodatnu aromu prikazuje piktogramom povezanim s tom aromom.
The process of any one of claims 1-18, wherein the hydrobromic acid in acetic acid solution is produced in a non-metallic reactor. 
Postupak prema jednom od patentnih zahtjeva 1-7, naznačen time, da se otopina priprema u nemetalnom reaktoru.
combining the cellulose fibres of step a) and the at least one filler of step b) at a weight ratio of fibres to filler on a dry weight basis of from 1:33 to 10:1; 
kombiniranja celuloznih vlakana iz koraka a) i barem jednog punila i/ili pigmenta iz koraka b);
the variable light chain sequence of SEQ ID NO: 97 and variable heavy chain sequence of SEQ ID NO: 111; or 
(m) varijabilno područje slabog lanca od sekvence SEQ ID NO: 97, 1 varijabilno područje jakog lanca od sekvence SEQ ID NO: 111; ili
The packaging and the device for manual rolling of cigarettes as claimed in Claim 9, characterized in that it can also be formed in a way that the base line (16) does not have the side (16a) and the side (16b). 
Pakiranje i uređaj za ručno motanje cigareta, prema zahtjevu 9, naznačen/o time, da može također biti oblikovan/o na takav način, da podna linija (16) ne sadrži stranu (164) i stranu (16b).
In like manner to that described in Example 15, the named compound (cis-racemate, m.p. 288-289°C.) was prepared from 2,4-dichlorobenzophenone. Example 21 
Na sličan način s onim koji je opisan u primjeru 15, napravljen je imenovani spoj (cis-acemat, t.t. 288-289*C) iz 2,4-diklorobenzofenona. Primjer 18
The pharmaceutical composition of claim 1, wherein the polymorphic form of the compound of Formula I is present in the composition in at least about 99 wt. %. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u najmanje99% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
This delay of the detaching action of the upper capsule ejector 25 and the lower capsule ejector 20, respectively, is defined by the corresponding designs of the control cam 37 of the shaft 16 and the bent control arm of the lower capsule ejector. 
Ovo kašnjenje postupka odvajanja gornje naprave za izbacivanje čahure 25 odnosno donje naprave za izbacivanje čahure 20 određeno je odgovarajućom izvedbom izbočenog dijela za upravljanje 37 osovine 16 i savijenom polugom za upravljanje donje naprave za izbacivanje čahure,
A high-energy feed pellet according to one or more of claims 1-3, characterised in that the feed pellet has a density of at most 700 g/l, preferably at most 630 g/l. 
Visoko-energetske hranjive pelete prema jednom ili više od zahtjeva 1-3, naznačeno time što hranjiva peleta ima gustoću najviše 630 g/l.
The method according to claim 1 wherein it is determined whether the selected or prepared mutant GPCR is able to bind a plurality of ligands of the same class as the ligand used in step (b) with a comparable spread or rank order of affinity as the parent GPCR. 
Metoda u skladu sa Zahtjevima 1-19 naznačena time da se utvrđuje je li odabrana ili pripremljena mutacija GPCRa sposobna vezati veći broj liganada iste skupine kao što je odabrani ligand koji se na usporediv način rasprostire ifili ima jednaki red sklonosti kao i izvorni GPCR.
The pharmaceutical composition according to claim 5 containing hyaluronidase. The pharmaceutical composition according to claim 6 containing polymers selected from hyaluronic acid and its derivatives, carboxymethylcellulose. 
Farmaceutski pripravak za upotrebu prema patentnim zahtjevima 3 - 5, koji sadržava polimere kao što je hijaluronska kiselina i njeni derivati, karboksimetilceluloza i/ili drugi polimeri prirodnog ili sintetičkog porijekla.
injecting gaseous carbon dioxide and a slurry into the feed water, wherein the slurry comprises micronized calcium carbonate and wherein the calcium carbonate has a particle size from 0.1 to 100 µm and a HCl insoluble content from 0.05 to 1.5 wt.-% based on the total weight of the micronized calcium carbonate. 
injektiranje plinovitog ugljik dioksida i mulja u ulaznu vodu, pri čemu mulj sadrži mikronizirani kalcij karbonat, gdje kalcij karbonat ima veličinu čestica od 0.1 do 100 µm.
Cy1 is optionally further substituted by one to three independent occurrences of R6, wherein each occurrence of R6 is —OMe, methyl, ethyl, F, or Cl. 
Cy! je izborno dalje supstituiran sa jednim do tri nezavisna R*, pri čemu je svaki R* jednak -OMe, metil, etil, F ili CI.
Next, 1 mL HF-pyridine solution was slowly charged to the reaction solution. 
Nadalje, 1 mL otopine HF-piridina bilo je polagano stavljano u otopinu reakcije.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound chlorothalonil. 
(A) spoja formule (I) naznačen time da R, je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i (B) barem jednog spoja odabranog iz skupine koja se sastoji od (Bl) - strobilurin fungicida.
The New Methylene Blue can be present in amounts sufficient to result in concentrations of about 70 uM to about 2.4 mM under staining conditions. 
Novo metilensko modrilo prisutno u dovoljnoj količini da se dobiju koncentracije od oko 70 uM do oko 2.4 MM u uvjetima bojenja; i
The method of claim 1, wherein the compounds are combined for a grouped or separate administration, simultaneously or sequentially. 
Smjesa prema zahtjevu 4 ili 5, gdje se spojevi kombiniraju za grupnu ili zasebnu primjenu, istodobno ili sekvencijski.
In one embodiment, an aforementioned method is provided wherein PSA is prepared by reacting an activated aminooxy linker with oxidized PSA; wherein the aminooxy linker is selected from the group consisting of: a 3-oxa-pentane-1,5-dioxyamine linker of the formula: a 3,6,9-trioxa-undecane-1,11-dioxyamine linker of the formula: and 
Postupak prema zahtjevu 2, pri čemu je polimer topljiv u vodi PSA i pri čemu je PSA pripremljen reagiranjem aktiviranog aminooksi veznika s oksidiranim PSA; pri čemu je aminooksi veznik odabran od skupine koja se sastoji od: a) 3-oksa-pentan-1,5-dioksiamin veznika formule: b) 3,6,9-trioksa-undekan-1, 11-dioksiamin veznika formule:
Receiving antenna 42 and transmitting antenna 44 comprise a supporting structure 50 (FIG. 2) defined by four adjacent elongated rectangular printed circuits 52 a, 52 b, 52 c, 52 d forming a rectangular frame structure. 
Prijemna antena 42 i predajna antena 44 sadrže oslonačku konstrukciju 50 (Slika 2), definiranu s četiri susjedna izdužena pravokutna štampana kruga 52a, 52b, 52c, 52d, koji oblikuju pravokutnu okvirnu konstrukciju.
A compound according to claim 1 in combination with an anti-inflammatory, bronchodilatory, anti-histamine or anti-tussive drug substance. A pharmaceutical composition comprising as active ingredient a compound according to claim 1 together with a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav, naznačen time, da kao aktivni sastojak obuhvaća spoj prema bilo kojem od zahtjeva 1 do 5, ili njegove stereoizomere ili njegove farmaceutski prihvatljive soli, zajedno s farmaceutski prihvatljivim razrjeđivačem ili nosačem.
wet-grinding the aqueous suspension as provided in step a) in at least one grinding step for obtaining an aqueous suspension of at least one calcium carbonate-comprising material having a weight median diameter d 50 < 0.5 µm; 
vlažnog usitnjavanja vodene suspenzije kao što je dobivena u koraku a) u najmanje jednom koraku usitnjavanja radi dobivanja vodene suspenzije najmanje jednog materijala koji sadrži kalcijev karbonat ponderiranog srednjeg promjera d50
According to a fifth aspect of the present invention a method for laying roofing or wall covering elements for producing a roofing or wall covering, having the following steps: 
Postupak za postavljanje krovnih elemenata ili elemenata zidnih obloga (1) za proizvodnju krovnog ili zidnog pokrova, naznačen time da ima slijedeće korake:
Chem. Res., 5:113-126 (1994)) investigated the specific binding of individual radio-labelled dihydrotetrabenazine isomers in the conscious rat brain. 
Chem, Res., 5:113-126 (1994)) su istražili specifično vezivanje pojedinih radiološki-označenih izomera u mozgu štakora pri svjesti.
The anti-photogreying additive such as a surfactant may be present in the photocatalytic dispersion in a range of 1-35 wt. %, preferably 1-15 wt. %, more preferably 1-5 wt. %. By including an anti-photogreying additive such as a surfactant in such concentrations, photogreying may be reduced, while the photocatalytic activity may be maintained at the same level or at least maintained to a level of at least 90% of the level that is achieved without the photogreying addition. The step of drying the resin impregnated paper may comprise drying said paper to a loss on cure of less than 20%, preferably less than 15%. 
Postupak prema zahtjevima od 1-3, naznačen time da je aditiv protiv promjene boje pod utjecajem svijetlosti prisutan u fotokatalitičkoj disperziji u rasponu od 1-35% težine, a poželjno je od 1-15% težine, a poželjnije je od 15% težine. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da sušenje impregniranog papira sa smolom (2) obuhvaća sušenje navedenog papira impregniranog sa smolom (2) do gubitka koji se pojavi stvrdnjavanjem ispod 20%, a poželjno je manje od 15%.
The reaction mixture was filtered, the precipitate re-dissolved in ethyl acetate and extracted with NaOH (2M), dried over MgSO4, filtered and evaporated. 
Reakcijska smjesa se filtrira, talog se ponovno otopi u etilnom acetatu i ekstrahira s NaOH (2 M), osuši preko MgSO,, filtrira i upari.